Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT

European Journal of Endocrinology

Volumn 169, Issue 4, 2013, Pages 421-430

  Alssema, Marjan ^a,b   Rijkelijkhuizen, Josina M ^a   Holst, Jens J ^c   Teerlink, Tom ^a   Scheffer, Peter G ^a   Eekhoff, Elisabeth M W ^a   Gastaldelli, Amalia ^d   Mari, Andrea ^e   M't Hart, Leen ^f   Nijpels, Giel ^a   Dekker, Jacqueline M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^e CNR   (Italy)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; MIXED MEAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS FUNCTION TEST; PRIORITY JOURNAL;

ADULT; AGED; ALANINE TRANSAMINASE; AREA UNDER CURVE; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; EATING; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; INCRETINS; LIPID METABOLISM; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84884848874     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0487     Document Type: Article

References (48)

1. Nauck M, Stockmann F, Ebert R & Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986 29 46-52. (doi:10.1007/BF02427280) (Pubitemid 16162741)
2. Vilsboll T, Krarup T, Madsbad S & Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002 45 1111-1119. (doi:10.1007/s00125-002-0878-6) (Pubitemid 34985287)
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R & Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation 1993 91 301-307. (doi:10.1172/JCI11 6186) (Pubitemid 23037285)
4. Zander M, Madsbad S, Madsen JL & Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and b-cell function in type 2 diabetes: a parallel-group study. Lancet 2002 359 824-830. (doi:10.1016/S0140-6736(02) 07952-7) (Pubitemid 34233752)
5. Calanna S, Christensen M, Holst JJ, Laferrere B, Gluud LL, Vilsboll T & Knop FK. Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and metaanalyses of clinical studies. Diabetologia 2013 56 965-972. (doi:10.1007/s00125-013-2841-0)
6. Nauck MA, Vardarli I, Deacon CF, Holst JJ & Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011 54 10-18. (doi:10.1007/ s00125-010-1896-4)
7. Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE & Meier JJ. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008 57 678-687. (doi:10.2337/db07-1124)
8. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK & Holst JJ. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 2001 86 3717-3723. (doi:10.1210/jc.86.8.3717) (Pubitemid 32755966)
9. Jones IR, Owens DR, Luzio S,Williams S & Hayes TM. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulindependent) diabetes mellitus. Diabetologia 1989 32 668-677. (doi:10.1007/BF00274255) (Pubitemid 19235993)
10. Lee S, Yabe D, Nohtomi K, Takada M, Morita R, Seino Y & Hirano T. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocrine Journal 2010 57 119-126. (doi:10.1507/endocrj. K09E-269)
11. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG & Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2003 88 2706-2713. (doi:10.1210/jc.2002- 021873) (Pubitemid 36724446)
12. Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K & Egan JM. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. American Journal of Physiology. Endocrinology and Metabolism 2006 290 E550-E559. (doi:10.1152/ajpendo.00326.2004) (Pubitemid 43671703)
13. Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J & Vilsboll T. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European Journal of Endocrinology 2006 155 485-493. (doi:10.1530/eje.1.02221) (Pubitemid 44463956)
14. Forst T, Weber MM & Pfutzner A. Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Experimental Diabetes Research 2012 2012 635472. (doi:10.1155/2012/635472)
15. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME & Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 2008 24 275-286. (doi:10.1185/0300 79908X253870) (Pubitemid 351160260)
16. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003 46 733-749. (doi:10.1007/ s00125-003-1111-y)
17. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010 375 1634-1639. (doi:10.1016/S0140-6736(10)60545-4)
18. Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE & Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006 49 452-458. (doi:10.1007/s00125-005-0126-y) (Pubitemid 43277867)
19. Courreges JP, Vilsboll T, Zdravkovic M, Le Thi T, Krarup T, Schmitz O, Verhoeven R, Buganova I & Madsbad S. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabetic Medicine 2008 25 1129-1131. (doi:10.1111/ j.1464-5491.2008.02484.x)
20. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rossner S et al. Safety, tolerability and sustained weight loss over 2 years with the oncedaily human GLP-1 analog, liraglutide. International Journal of Obesity 2012 36 843-854. (doi:10.1038/ijo.2011.158)
21. Ding X, Saxena NK, Lin S, Gupta NA & Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006 43 173-181. (doi:10.1002/hep.21006) (Pubitemid 43733604)
22. Flatt PR. Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes? Diabetic Medicine 2008 25 759-764. (doi:10.1111/j.1464-5491.2008.02455.x)
23. McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA & Flatt PR. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. American Journal of Physiology. Endocrinology and Metabolism 2007 293 E1746-E1755. (doi:10.1152/ajpendo.00460.2007) (Pubitemid 350255128)
24. Clements RH, Gonzalez QH, Long CI, Wittert G & Laws HL. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. American Surgeon 2004 70 1-4.
25. Rijkelijkhuizen JM, Girman CJ, Mari A, Alssema M, Rhodes T, Nijpels G, Kostense PJ, Stein PP, Eekhoff EM, Heine RJ et al. Classical and model-based estimates of b-cell function during a mixed meal vs. an OGTT in a population-based cohort. Diabetes Research and Clinical Practice 2009 83 280-288. (doi:10.1016/j.diabres.2008.11.017)
26. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF consultation 2006.
27. Nauck MA, El-Ouaghlidi A, Gabrys B, Hucking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE & Meier JJ. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regulatory Peptides 2004 122 209-217. (doi:10.1016/j.regpep. 2004.06.020) (Pubitemid 39371171)
28. Deacon CF, Nauck MA, Meier J, Hucking K & Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. Journal of Clinical Endocrinology and Metabolism 2000 85 3575-3581. (doi:10.1210/jc.85.10.3575)
29. Mari A, Pacini G, Murphy E, Ludvik B & Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001 24 539-548. (doi:10.2337/diacare.24.3.539) (Pubitemid 32198427)
30. Twisk J. Applied longitudinal data analysis for epidemiology: a practical guide. Cambridge University Press, 2006.
31. Cho YM & Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 2011 54 219-222. (doi:10.1007/s00125-010-1986-3)
32. Faerch K, Vaag A, Holst JJ, Glumer C, Pedersen O & Borch-Johnsen K. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic a and b cell function but differential roles of incretin hormones and insulin action. Diabetologia 2008 51 853-861. (doi:10.1007/s00125-008-0951-x)
33. Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Vanttinen M, Stancakova A, Jansson PA, Pellme F, Holst JJ, Kuulasmaa T et al. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 2008 51 502-511. (doi:10.1007/s00125-007-0899-2)
34. Deacon CF.What do we know about the secretion and degradation of incretin hormones? Regulatory Peptides 2005 128 117-124. (doi:10.1016/j.regpep.2004.06. 007) (Pubitemid 40380912)
35. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R & Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996 38 916-919. (doi:10.1136/gut.38. 6.916) (Pubitemid 26231779)
36. Dube PE & Brubaker PL. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Hormone and Metabolic Research 2004 36 755-760. (doi:10.1055/s-2004-826159) (Pubitemid 40115895)
37. Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G, Mari A & Ahren B. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. Journal of Clinical Endocrinology and Metabolism 2011 96 2519-2524. (doi:10.1210/jc.2011-0266)
38. Horowitz M, Wishart JM, Jones KL & Hebbard GS. Gastric emptying in diabetes: an overview. Diabetic Medicine 1996 13 S16-S22.
39. Phillips WT, Schwartz JG & McMahan CA. Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. Journal of Nuclear Medicine 1992 33 1496-1500.
40. Ahren B, Larsson H & Holst JJ. Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausalwomen with impaired glucose tolerance. European Journal of Endocrinology 1997 137 127-131. (doi:10.1530/eje.0.1370127) (Pubitemid 27342226)
41. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, Holst JJ & Ferrannini E. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008 57 1340-1348. (doi:10.2337/db07-1315)
42. Hansen KB, Vilsboll T, Bagger JI, Holst JJ & Knop FK. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2012 97 1363-1370. (doi:10.1210/jc.2011-2594)
43. Holst JJ, Knop FK, Vilsboll T, Krarup T & Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011 34 (Suppl 2) S251-S257. (doi:10.2337/dc11-s227)
44. Vilsboll T, Krarup T, Deacon CF, Madsbad S & Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001 50 609-613. (doi:10.2337/diabetes. 50.3.609) (Pubitemid 32195226)
45. Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U & Knop FK. Regulation of glucagon secretion by incretins. Diabetes, Obesity and Metabolism 2011 13 (Suppl 1) 89-94. (doi:10.1111/j.1463-1326.2011.01452.x)
46. Hansen L, Hartmann B, Mineo H & Holst JJ. Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regulatory Peptides 2004 118 11-18. (doi:10.1016/j.regpep.2003.10.021) (Pubitemid 38167361)
47. Brons C, Jensen CB, Storgaard H, Hiscock NJ, White A, Appel JS, Jacobsen S, Nilsson E, Larsen CM, Astrup A et al. Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men. Journal of Physiology 2009 587 2387-2397. (doi:10.1113/jphysiol.2009.169078)
48. Irwin N & Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009 52 1724-1731. (doi:10.1007/s00125- 009-1422-8)